Exchange: NASDAQ·Updated 07:53 PM EDT

JAZZ News

News
all
press releases
Cramer's lightning round: 'I'm going to say yes to Jazz Pharmaceuticals'
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...
CNBC: Mad Money with Jim Cramer
Cramer's lightning round: 'I'm going to say yes to Jazz Pharmaceuticals'
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...
CNBC: Mad Money with Jim Cramer
More News
Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Zacks
ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know
AbCellera shares skyrocket 121% as positive ABCL635 data, major partnerships and a stronger financial position boost investor confidence.
Zacks
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences
Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences Jazz Pharmaceuticals Completes Acquisition of Actio BiosciencesPR NewswireDUBLIN, Sept. 15, 2026 Acquisition adds ABS-1230, a clinical-stage, potential first-in-class precision therapy for KCNT1-related epilepsyTransaction strengthens...
PR Newswire
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
Zacks
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences
Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences PR Newswire DUBLIN, Sept. 2, 2026 DUBLIN, Sept. 2, 2026 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that company management will...
PR Newswire
Why Is Jazz (JAZZ) Down 6.9% Since Last Earnings Report?
Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Axsome Begins Phase III Study on AXS-05 for Smoking Cessation
AXSM begins dosing in the phase III SUMMIT study investigating AXS-05 for treating smoking cessation in adults.
Zacks
JAZZ Rises on Updated OS Results From Gastric Cancer Study
Jazz up as updated HERIZON-GEA-01 results show statistically significant OS benefits for Ziihera-based regimens in first-line HER2+ gastroesophageal adenocarcinoma.
Zacks
Ziihera (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA
Ziihera (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus Trastuzumab plus Chemotherapy in First-Line HER2+ Advanced GEA Ziihera (zanidatamab-hrii) plus Chemotherapy Demonstrates Statistically Significant Overall Survival Benefit Versus...
PR Newswire

Advertisement|Remove ads.